XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$8.74
0.04 (0.46%)
▲
5d:
+2.58%
30d:
+5.05%
90d:
+41.2%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XERS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XERS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.49
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $8.74, which is considered extended relative to its 30-day fair value range of $8.07 to $8.70. From a valuation perspective, the stock is trading at a premium (Forward PE: 22.4) compared to its historical average (19.2). At these levels, the market is pricing in 5.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $7.96, while resistance sits at $9.02.
Market Sentiment: XERS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.71 (+34.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $7.96, while resistance sits at $9.02.
Market Sentiment: XERS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.71 (+34.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.07 -
$8.70
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
27.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.0% below Wall St target ($11.71)
- NEUTRAL: Trading at premium valuation - market expects 5.3% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.07 -
$8.70
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.96
Resistance Level
$9.02
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.41
Wall Street Target
$11.71
(+34.0%)
Revenue Growth (YoY)
28.7%
Profit Margin
-5.1%
Valuation Premium vs History
+5.3% premium
PE vs Historical
22.4 vs 19.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.3%
(market-implied from PE analysis)
1-Year Target
$9.20
(+5%)
2-Year Target
$9.69
(+11%)
3-Year Target
$10.20
(+17%)
3-Yr Target (if PE normalizes)
(PE: 22→19)
PE COMPRESSION
$8.74
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 24, 2026 5:32 PM ET
Data refreshes hourly during market hours. Next update: 6:32 PM
Data refreshes hourly during market hours. Next update: 6:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Beth Hecht
SELL
16667 shares
2026-03-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |